Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyBiologicalProcessB cell differentiation

YY1AP1 GON4L

2.55e-0320182GO:0030183
GeneOntologyBiologicalProcessfertilization

TTLL5 FOXL2

4.31e-0326382GO:0009566
GeneOntologyCellularComponentIno80 complex

YY1AP1 GON4L

1.74e-051782GO:0031011
GeneOntologyCellularComponentINO80-type complex

YY1AP1 GON4L

4.82e-052882GO:0097346
GeneOntologyCellularComponentSWI/SNF superfamily-type complex

YY1AP1 GON4L

5.74e-049682GO:0070603
GeneOntologyCellularComponentATPase complex

YY1AP1 GON4L

1.03e-0312982GO:1904949
GeneOntologyCellularComponentfibrillar center

YY1AP1 GON4L

1.50e-0315682GO:0001650
GeneOntologyCellularComponentnuclear chromosome

YY1AP1 GON4L

3.92e-0325482GO:0000228
MousePhenoincreased salivary adenocarcinoma incidence

YY1AP1 GON4L

2.15e-07272MP:0000621
MousePhenoincreased salivary gland tumor incidence

YY1AP1 GON4L

2.15e-06572MP:0010318
MousePhenoincreased mouth tumor incidence

YY1AP1 GON4L

3.22e-06672MP:0003750
MousePhenoincreased facial tumor incidence

YY1AP1 GON4L

4.51e-06772MP:0008018
MousePhenoabsent B cells

YY1AP1 GON4L

1.95e-051472MP:0008071
MousePhenodecreased spleen white pulp amount

YY1AP1 GON4L

1.20e-043472MP:0008479
MousePhenodecreased pro-B cell number

YY1AP1 GON4L

2.20e-044672MP:0008208
MousePhenoarrested B cell differentiation

YY1AP1 GON4L

2.20e-044672MP:0001802
MousePhenoincreased alimentary system tumor incidence

YY1AP1 GON4L

4.40e-046572MP:0010292
MousePhenoabnormal salivary gland morphology

YY1AP1 GON4L

6.18e-047772MP:0000613
MousePhenoabnormal pro-B cell morphology

YY1AP1 GON4L

6.34e-047872MP:0005432
MousePhenodecreased immature B cell number

YY1AP1 GON4L

9.00e-049372MP:0008215
MousePhenoabnormal merocrine gland morphology

YY1AP1 GON4L

9.78e-049772MP:0013544
MousePhenoincreased adenocarcinoma incidence

YY1AP1 GON4L

1.10e-0310372MP:0009308
MousePhenoabnormal immature B cell number

YY1AP1 GON4L

1.47e-0311972MP:0013664
MousePhenoabnormal immature B cell morphology

YY1AP1 GON4L

1.57e-0312372MP:0005022
MousePhenospleen hypoplasia

YY1AP1 GON4L

1.70e-0312872MP:0000694
MousePhenoincreased gland tumor incidence

YY1AP1 GON4L

2.00e-0313972MP:0010288
MousePhenoincreased carcinoma incidence

YY1AP1 GON4L

3.96e-0319772MP:0002038
MousePhenoincreased malignant tumor incidence

YY1AP1 GON4L

5.68e-0323772MP:0002018
Pubmed

Newly identified Gon4l/Udu-interacting proteins implicate novel functions.

YY1AP1 GON4L

4.63e-0828232848183
Pubmed

The transcriptional regulator GON4L is required for viability and hematopoiesis in mice.

YY1AP1 GON4L

4.63e-0828233864850
Pubmed

The Justy mutation identifies Gon4-like as a gene that is essential for B lymphopoiesis.

YY1AP1 GON4L

4.63e-0828220530203
Pubmed

The Justy mutant mouse strain produces a spontaneous murine model of salivary gland cancer with myoepithelial and basal cell differentiation.

YY1AP1 GON4L

1.39e-0738223608756
Pubmed

Early B Cell Progenitors Deficient for GON4L Fail To Differentiate Due to a Block in Mitotic Cell Division.

YY1AP1 GON4L

1.39e-0738228381640
Pubmed

The developmental regulator protein Gon4l associates with protein YY1, co-repressor Sin3a, and histone deacetylase 1 and mediates transcriptional repression.

YY1AP1 GON4L

4.63e-0758221454521
Cytoband1q22

YY1AP1 GON4L

4.22e-0557821q22
CytobandEnsembl 112 genes in cytogenetic band chr1q22

YY1AP1 GON4L

6.56e-057182chr1q22
CoexpressionTERAMOTO_OPN_TARGETS_CLUSTER_5

YY1AP1 GON4L

2.28e-06882MM522
CoexpressionDESCARTES_MAIN_FETAL_INHIBITORY_INTERNEURONS

ANO4 ROBO3

4.28e-053382M40085
ToppCellfrontal_cortex-Neuronal-glutamatergic_neuron-L5_PT|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype

ANO4 ROBO3

2.44e-0413482cb676d5bbc468bd3ce1b6712d41c986ee9221ac5
ToppCell343B-Myeloid-Macrophage-SPP1+_Macrophage_4|Myeloid / Donor, Lineage, Cell class and subclass (all cells)

TTLL5 GON4L

2.47e-0413582c4d3c9eba2a85ac40fea5ecfcc2b442a472323d0
ToppCellFetal_brain-organoid_Tanaka_cellReport-GW16-Mesenchymal-Mesoderm|GW16 / Sample Type, Dataset, Time_group, and Cell type.

ANO4 CCDC71L

2.62e-0413982d441c29852c28928ecb696b4b95e31b30c17116b
ToppCelldroplet-Lung-21m-Hematologic-lymphocytic-CD8-positive,_alpha-beta_T_cell-CD8-positive,_alpha-beta_T_cell_l21|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

ESYT2 CCDC71L

4.20e-041768291ad2c34144f72283ca112fd3b3784f2f6259f65
ToppCellTCGA-Lung-Primary_Tumor-Lung_Carcinoma-Lung_Adenocarcinoma_Mixed_Subtype-4|TCGA-Lung / Sample_Type by Project: Shred V9

ESYT2 CCDC71L

4.20e-04176820923b01137d6f9956ca815b41102c81e82624065
ToppCellE18.5-Endothelial-Endothelial_lymphatic-Lymphatic_EC|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ESYT2 ROBO3

4.24e-04177828dfadd9852e0c256363471a7cfe6af120c8c51e0
ToppCellE18.5-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC-LEC_mature|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ESYT2 ROBO3

4.24e-0417782767b2af5f224d100b22bed32f86cec1cd17e8711
ToppCellE18.5-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ESYT2 ROBO3

4.24e-04177825ef2527e9b41e62f1724cdabaad9d8979266bb7d
ToppCellE18.5-Endothelial-Endothelial_lymphatic|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ESYT2 ROBO3

4.24e-0417782ae1d2fdd4f67f50c906b27ea084de058c6908aa2
ToppCellBAL-Control-cDC_8|Control / Compartment, Disease Groups and Clusters

TTLL5 ROBO3

4.44e-0418182f370161afef2ec827a7b194c06abb9ac1a507cbb
ToppCellMid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L5-6_SST_KLHL14|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

ANO4 FOXL2

4.53e-0418382439b1d1373b7cc73d65f3b59037a6def7cf8f4ba
ToppCell3'-Broncho-tracheal-Immune_Myeloid-Myeloid_macrophage-elicited_macrophage-Monocyte-derived_macrophage-Monocyte-derived_macrophage_L.1.2.5.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

CCDC71L FOXL2

4.58e-0418482d1ea2b60fb1ca1a0b809d131310c43903a9e84ce
ToppCell-Unknown-Endothelial-Myofibroblast| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANO4 TTLL5

4.78e-04188826468fa95ad0395395301115286f2d8c0df5d3882
ToppCell-Unknown-Endothelial| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANO4 TTLL5

4.78e-04188827a81ac5c79c3eb26639b52d2b9fd5e7ef9798fd6
ToppCell-Unknown| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANO4 TTLL5

4.78e-04188829cb718bfe1358c6fd842f096e228eb0abb9aefc6
ToppCellPCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature4_(1)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung

ANO4 ESYT2

4.99e-04192826bba80887d6f64cf913a5c22f62baaddda417ce0
ToppCellLPS_anti-TNF-Mesenchymal_myocytic-Myofibroblastic|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

ANO4 ESYT2

5.36e-0419982e9820d5fb4e8b46973c4c50ac5db8fb4a1bf603b
ToppCellLPS_IL1RA-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

ANO4 ESYT2

5.41e-04200828988f113708eef7d9d2a6a6c1bcfd7c8f9804d3e
ToppCellLPS_anti-TNF-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

ANO4 ESYT2

5.41e-0420082c596a53c0b63c9deaac7d99fcbdd94ecfa96b86c
ToppCellLPS_IL1RA-Mesenchymal_myocytic-Myofibroblastic|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

ANO4 ESYT2

5.41e-042008287827041663013f5e7273168dc8709d69840e7ce
ToppCellLPS_only-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|LPS_only / Treatment groups by lineage, cell group, cell type

ANO4 ESYT2

5.41e-0420082593bf6a7c557437db9a9249a5058a46014179ef6
ToppCellNeuronal-Inhibitory-iB-iB_4(SST)-GXYLT2-|Neuronal / cells hierarchy compared to all cells using T-Statistic

ANO4 FOXL2

5.41e-0420082fe63aa1febd2bf650a7dd4e8b4420063580644ba
ToppCellLPS_only-Mesenchymal_myocytic-Myofibroblastic|LPS_only / Treatment groups by lineage, cell group, cell type

ANO4 ESYT2

5.41e-042008202cae2c296a13ad4cbb53bca7a86d64629d67d66
ToppCellLPS_IL1RA_TNF-Mesenchymal_myocytic-Myofibroblastic|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

ANO4 ESYT2

5.41e-042008208bf8c00eee6468215edb3611296bfc8784c4d56
ToppCellControl_saline-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|Control_saline / Treatment groups by lineage, cell group, cell type

ANO4 ESYT2

5.41e-0420082c5e051f1aac8dda376c342a9932785a23450e073
ToppCellLPS_only-Mesenchymal_myocytic|LPS_only / Treatment groups by lineage, cell group, cell type

ANO4 ESYT2

5.41e-04200828bc9923f82bfb836e2f524204c92050edeae8ca5
ToppCellNeuronal-Inhibitory-iB-iB_4(SST)-GXYLT2|Neuronal / cells hierarchy compared to all cells using T-Statistic

ANO4 FOXL2

5.41e-042008237728d83b246dd70933d1f52f938bc1c401df7b9
ToppCellNeuronal-Inhibitory-iB-iB_4(SST)-GXYLT2--L4-6|Neuronal / cells hierarchy compared to all cells using T-Statistic

ANO4 FOXL2

5.41e-0420082cafa1b46d0b052fca6191ad99d5862a07d0a1fd2
ToppCellLPS_IL1RA_TNF-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

ANO4 ESYT2

5.41e-0420082dcdaec3ca3a3024dc1b8788c417003f84c2bffdc
ComputationalGenes in the cancer module 397.

GON4L ROBO3

7.43e-0412142MODULE_397
DrugAztreonam [78110-38-0]; Down 200; 9.2uM; PC3; HT_HG-U133A

TTLL5 GON4L ROBO3

3.31e-05194832118_DN
DrugPiroxicam [36322-90-4]; Down 200; 12uM; PC3; HT_HG-U133A

TTLL5 GON4L ROBO3

3.41e-05196832089_DN
DrugProscillaridin A [466-06-8]; Up 200; 7.6uM; HL60; HT_HG-U133A

TTLL5 GON4L

1.40e-03164822920_UP
DrugAdiphenine hydrochloride [50-42-0]; Down 200; 11.4uM; MCF7; HT_HG-U133A

TTLL5 GON4L

1.74e-03183821709_DN
DrugLansoprazole [103577-45-3]; Down 200; 10.8uM; HL60; HT_HG-U133A

TTLL5 GON4L

1.86e-03189822967_DN
Drugcarbamazepine; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA

TTLL5 GON4L

1.88e-0319082952_UP
Drugradicicol, diheterospora chlamydosporia; Up 200; 0.1uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

1.88e-03190825579_UP
DrugTranylcypromine hydrochloride [1986-47-6]; Down 200; 23.6uM; PC3; HT_HG-U133A

TTLL5 GON4L

1.92e-03192822101_DN
DrugSC 19220; Down 200; 10uM; PC3; HT_HG-U133A

TTLL5 GON4L

1.92e-03192827065_DN
DrugTetrahydroalstonine [6474-90-4]; Up 200; 11.4uM; MCF7; HT_HG-U133A

TTLL5 GON4L

1.94e-03193826209_UP
DrugU-62066 [87151-85-7]; Up 200; 1uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

1.94e-03193823901_UP
DrugCarbachol [51-83-2]; Up 200; 21.8uM; MCF7; HT_HG-U133A

TTLL5 GON4L

1.96e-03194825342_UP
Drug5252917; Up 200; 14uM; MCF7; HT_HG-U133A_EA

TTLL5 ROBO3

1.96e-0319482828_UP
DrugHydroxytacrine maleate (R,S) [118909-22-1]; Down 200; 12.2uM; HL60; HT_HG-U133A

TTLL5 GON4L

1.96e-03194822430_DN
DrugMephenytoin [50-12-4]; Down 200; 18.4uM; MCF7; HT_HG-U133A

TTLL5 GON4L

1.98e-03195823580_DN
DrugPivmecillinam hydrochloride [32887-03-9]; Down 200; 8.4uM; HL60; HT_HG-U133A

TTLL5 GON4L

1.98e-03195822973_DN
DrugHalofantrine hydrochloride [36167-63-2]; Up 200; 7.4uM; MCF7; HT_HG-U133A

GON4L ROBO3

1.98e-03195827469_UP
DrugIsosorbide dinitrate [87-33-2]; Down 200; 17uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

1.98e-03195824742_DN
DrugIproniazide phosphate [305-33-9]; Down 200; 14.4uM; PC3; HT_HG-U133A

TTLL5 GON4L

1.98e-03195822125_DN
DrugRisperidone [106266-06-2]; Up 200; 9.8uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

1.98e-03195827449_UP
DrugPentoxifylline [6493-05-6]; Down 200; 14.4uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

1.98e-03195822290_DN
DrugPramoxine hydrochloride [637-58-1]; Down 200; 12.2uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

1.98e-03195824368_DN
DrugMetrizamide [31112-62-6]; Down 200; 5uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

1.98e-03195824156_DN
DrugNaringenine [480-41-1]; Down 200; 14.6uM; PC3; HT_HG-U133A

TTLL5 GON4L

1.98e-03195824597_DN
DrugPregnenolone [145-13-1]; Down 200; 12.6uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.00e-03196824802_DN
DrugOrphenadrine hydrochloride [341-69-5]; Down 200; 13uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.00e-03196824359_DN
DrugPiretanide [55837-27-9]; Down 200; 11uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.00e-03196823567_DN
Drug(d,l)-Tetrahydroberberine [522-97-4]; Down 200; 11.8uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.00e-03196822818_DN
DrugEucatropine hydrochloride [536-93-6]; Up 200; 12.2uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.00e-03196823416_UP
DrugMiconazole [22916-47-8]; Down 200; 9.6uM; PC3; HT_HG-U133A

TTLL5 GON4L

2.00e-03196826615_DN
DrugSB 202190; Up 200; 1uM; PC3; HT_HG-U133A

TTLL5 GON4L

2.00e-03196826882_UP
DrugDizocilpine maleate [77086-22-7]; Down 200; 11.8uM; MCF7; HT_HG-U133A

GON4L ROBO3

2.00e-03196822232_DN
DrugTranexamic acid [1197-18-8]; Down 200; 25.4uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.00e-03196822248_DN
DrugMethacycline hydrochloride [3963-95-9]; Up 200; 8.4uM; MCF7; HT_HG-U133A

GON4L ROBO3

2.00e-03196827321_UP
DrugCefotaxime sodium salt [64485-93-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A

GON4L ROBO3

2.02e-03197822235_DN
Drugestradiol, USP; Down 200; 0.01uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.02e-03197826957_DN
Drug3-alpha-Hydroxy-5-beta-androstan-17-one [53-42-9]; Down 200; 13.8uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.02e-03197826060_DN
DrugKynurenine, 3-hydroxy (R,S) [2147-61-7]; Up 200; 17.8uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.02e-03197822654_UP
DrugCyclizine hydrochloride [303-25-3]; Up 200; 13.2uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.02e-03197822880_UP
DrugAlprenolol hydrochloride [13707-88-5]; Up 200; 14uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.02e-03197823188_UP
DrugDydrogesterone [152-62-5]; Down 200; 12.8uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.02e-03197824836_DN
DrugRoxithromycin [80214-83-1]; Up 200; 4.8uM; HL60; HT_HG-U133A

TTLL5 ROBO3

2.02e-03197822992_UP
DrugCanrenoic acid potassium salt [2181-04-6]; Down 200; 10uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.02e-03197822228_DN
DrugNeostigmine bromide [114-80-7]; Down 200; 13.2uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.04e-03198823294_DN
DrugNorethynodrel [68-23-5]; Up 200; 13.4uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.04e-03198827471_UP
DrugPhensuximide [86-34-0]; Up 200; 21.2uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.04e-03198823521_UP
DrugMetformin hydrochloride [1115-70-4]; Down 200; 24.2uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.04e-03198821694_DN
DrugPronethalol hydrochloride [51-02-5]; Up 200; 15uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.04e-03198827322_UP
DrugDimethisoquin hydrochloride [2773-92-4]; Down 200; 13uM; MCF7; HT_HG-U133A

GON4L ROBO3

2.04e-03198824791_DN
DrugTetramisole hydrochloride [16595-80-5]; Up 200; 16.6uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.04e-03198822849_UP
DrugCalciferol [50-14-6]; Down 200; 10uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.04e-03198823304_DN
DrugMethantheline bromide [53-46-3]; Down 200; 9.6uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.04e-03198823560_DN
DrugAmitryptiline hydrochloride [549-18-8]; Up 200; 12.8uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.04e-03198825453_UP
DrugPrednicarbate [73771-04-7]; Down 200; 8.2uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.04e-03198823542_DN
DrugLycorine hydrochloride [2188-68-3]; Up 200; 12.4uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.04e-03198823891_UP
DrugPyrantel tartrate [33401-94-4]; Down 200; 11.2uM; PC3; HT_HG-U133A

TTLL5 GON4L

2.04e-03198822097_DN
DrugMethotrimeprazine maleat salt [7104-38-3]; Down 200; 9uM; PC3; HT_HG-U133A

TTLL5 GON4L

2.04e-03198827399_DN
DrugN-Acetyl-DL-homocysteine Thiolactone [1195-16-0]; Down 200; 25.2uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.04e-03198826031_DN
Drug(+,-)-Synephrine [94-07-5]; Down 200; 24uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.04e-03198823578_DN
DrugRiluzole hydrochloride; Down 200; 14.8uM; PC3; HT_HG-U133A

GON4L ROBO3

2.04e-03198823666_DN
DrugMetampicillin sodium salt [6489-61-8]; Down 200; 10.4uM; PC3; HT_HG-U133A

TTLL5 GON4L

2.04e-03198822123_DN
Drugretinoic acid; Down 200; 1uM; PC3; HT_HG-U133A

TTLL5 GON4L

2.04e-03198824435_DN
DrugTetracycline hydrochloride [64-75-5]; Down 200; 8.4uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.06e-03199822243_DN
DrugNicergoline; Down 200; 8.2uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.06e-03199822220_DN
DrugOxaprozin [21256-18-8]; Down 200; 13.6uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.06e-03199824352_DN
DrugAtracurium besylate [64228-81-5]; Down 200; 3.2uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.06e-03199821702_DN
DrugAdenosine 5'-monophosphate monohydrate [18422-05-4]; Up 200; 11uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.06e-03199825359_UP
DrugDoxazosin mesylate [77883-43-3]; Up 200; 7.4uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.06e-03199824988_UP
Drugnordihydroguaiaretic acid; Down 200; 1uM; HL60; HT_HG-U133A

TTLL5 GON4L

2.06e-03199822683_DN
Drugvaldecoxib; Down 200; 10uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.06e-03199826403_DN
DrugDihydrostreptomycin sulfate [5490-27-7]; Down 200; 2.8uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.06e-03199822237_DN
DrugMethiazole; Up 200; 15uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.06e-03199823878_UP
DrugLetrozole [112809-51-5]; Up 200; 14uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.06e-03199827336_UP
DrugMoxisylyte hydrochoride [964-52-3]; Down 200; 12.6uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.08e-03200821682_DN
DrugFenoterol hydrobromide [1944-12-3]; Up 200; 10.4uM; MCF7; HT_HG-U133A

TTLL5 ROBO3

2.08e-03200825432_UP
DrugEpirizole [18694-40-1]; Down 200; 17uM; MCF7; HT_HG-U133A

TTLL5 GON4L

2.08e-03200821681_DN
DrugPropylthiouracil [51-52-5]; Down 200; 23.4uM; PC3; HT_HG-U133A

TTLL5 ROBO3

2.08e-03200824076_DN
Diseasesalivary gland cancer (implicated_via_orthology)

YY1AP1 GON4L

6.43e-08282DOID:8850 (implicated_via_orthology)
Diseaseimmature platelet count

ESYT2 CCDC71L

3.53e-0410682EFO_0803544
Diseaseimmature platelet fraction

ESYT2 CCDC71L

4.08e-0411482EFO_0009187
Diseasediffuse plaque measurement

ANO4 CCDC71L ROBO3

8.59e-0475883EFO_0010699
Diseaseage at menopause

ESYT2 CCDC71L

2.81e-0330282EFO_0004704
Diseaseplatelet measurement

ESYT2 CCDC71L

3.05e-0331582EFO_0005036
Diseaseserum gamma-glutamyl transferase measurement

YY1AP1 GON4L

2.37e-0291482EFO_0004532

Protein segments in the cluster

PeptideGeneStartEntry
RMYLLPDKRRSGRRK

ESYT2

826

A0FGR8
VRMPFRRKIYYLPRR

ANO4

181

Q32M45
GNYRRRRRMKRPFRP

FOXL2

141

P58012
RKPYVRRRPSKRRGV

GON4L

1111

Q3T8J9
MRRSMKRRRRRRPVA

CCDC71L

1

Q8N9Z2
RARFRKKPKALPYRR

ROBO3

1246

Q96MS0
MFRKPYVRRRPSKRR

YY1AP1

566

Q9H869
RRSSRLRAMRPKYPV

TTLL5

556

Q6EMB2